Valiltramiprosate

Last updated

Valiltramiprosate
Valiltramiprosate.svg
Clinical data
Other namesALZ-801; BLU8499
Legal status
Legal status
  • Investigational
Identifiers
  • 3-[[(2S)-2-amino-3-methylbutanoyl]amino]propane-1-sulfonic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C8H18N2O4S
Molar mass 238.30 g·mol−1
3D model (JSmol)
  • CC(C)[C@@H](C(=O)NCCCS(=O)(=O)O)N
  • InChI=1S/C8H18N2O4S/c1-6(2)7(9)8(11)10-4-3-5-15(12,13)14/h6-7H,3-5,9H2,1-2H3,(H,10,11)(H,12,13,14)/t7-/m0/s1
  • Key:NRZRFNYKMSAZBI-ZETCQYMHSA-N

Valiltramiprosate is an investigational new drug that is being evaluated to treat early Alzheimer's disease. [1] It is an amyloid precursor protein antagonist. [2] Phase III results published in late 2025 suggested valiltramiprosate offered some benefit to certain patients genetically predisposed to Alzheimers, primarily when the drug was taken before those paients had developed dementia. [3]

Valitramiprosate is being developed by drug maker Alzheon.

References

  1. ↑ "Valiltramiprosate - Alzheon". AdisInsight. Springer Nature Switzerland AG.
  2. ↑ Lee D, Antonsdottir IM, Clark ED, Porsteinsson AP (May 2024). "Review of valiltramiprosate (ALZ-801) for the treatment of Alzheimer's disease: a novel small molecule with disease modifying potential". Expert Opinion on Pharmacotherapy. 25 (7): 791–799. doi:10.1080/14656566.2024.2360069. PMID   38814590.
  3. ↑ Hamilton J (29 October 2025). "An Alzheimer's pill appears to protect some in a high-risk population". NPR . Retrieved 29 October 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.